EDINBURGH, Scotland--(BUSINESS WIRE)--Stem Cell Sciences plc (SCS) (AIM:STEM) (ASX:STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies, is pleased to announce the exclusive in-licensing of a breakthrough technology. This is expected to significantly accelerate the application of human embryonic stem (ES) cells in both research and cell-based therapies. This discovery overcomes the key challenge in the effective scale-up of stem cell technologies – cell death. When separated from one another, during transfer from one growth vessel to another in routine laboratory processes such as scale-up and genetic modification, human ES cells commonly undergo cell death. The use of a selective ROCK inhibitor to increase the robustness of the cells will allow for the large-scale automated production that is needed for industrial research and clinical application. SCS has secured exclusive rights to the discovery in all global territories except Japan where the company holds non-exclusive rights. Financial terms were not disclosed.
